/AMGEN%20Inc_%20logo%20on%20meds-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
With a market cap of $149.1 billion, Amgen Inc. (AMGN) is renowned for its innovative human therapeutics across oncology, cardiovascular, inflammation, bone health, and nephrology. With a robust product portfolio, including blockbusters like Enbrel, Prolia, Repatha, and Neulasta, and a strong pipeline of cancer drugs, Amgen continues to drive growth through cutting-edge science, strategic acquisitions, and biosimilar development.
The Thousand Oaks, California-based company is expected to release its fiscal Q1 2025 earnings results after the market closes on Thursday, May 1. Ahead of this event, analysts expect AMGN to report a profit of $4.15 per share, up 4.8% from $3.96 per share in the prior year's quarter. It has surpassed Wall Street's bottom-line estimates in the past four quarters. In Q4 2024, Amgen exceeded the consensus EPS estimate by 5.6%.